Advanced

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study

Federici, AB; Mazurier, C; Berntorp, Erik LU ; Lee, CA; Scharrer, I; Goudemand, J; Lethagen, S; Nitu, I; Ludwig, G and Hilbert, L, et al. (2004) In Blood 103(6). p.2032-2038
Abstract
This study prospectively evaluated the rate of biologic response to desmopressin (DDAVP) in 66 patients with type I or 2 von Willebrand disease (VWD), each of whom had, on the basis of available records, a clinically significant bleeding history and at least one of the following laboratory abnormalities: bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity (VWF:RCo) less than 10 IU/dL, factor VIII coagulant activity (FVIII:C) less than 20 IU/dL (severe VWD). Before the study, responsive patients were defined as those who, 2 hours after infusion of 0.3 mug/kg DDAVP, had increased baseline values of VWF:RCo and FVIII:C by at least 3-fold and achieved levels of at least 30 IU/dL for both and a BT of 12 minutes or less. The... (More)
This study prospectively evaluated the rate of biologic response to desmopressin (DDAVP) in 66 patients with type I or 2 von Willebrand disease (VWD), each of whom had, on the basis of available records, a clinically significant bleeding history and at least one of the following laboratory abnormalities: bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity (VWF:RCo) less than 10 IU/dL, factor VIII coagulant activity (FVIII:C) less than 20 IU/dL (severe VWD). Before the study, responsive patients were defined as those who, 2 hours after infusion of 0.3 mug/kg DDAVP, had increased baseline values of VWF:RCo and FVIII:C by at least 3-fold and achieved levels of at least 30 IU/dL for both and a BT of 12 minutes or less. The rate of biologic response varied according to VWD types and was higher in type 1 (7 of 26, 27%) than in type 2 (7 of 40,18%) (type 2A [1 of 15, 7%], type 2M [3 of 21, 14%], type 2N [3 of 4,75%]). Mutations in the VWF gene were previously known or newly identified in most patients with types 2A (n = 15 of 15), 2M (n = 15 of 21), and 2N (n = 4 of 4), but in none of those with type 1 VWD. Genotype provided more information than phenotype in predicting individual responses to DDAVP only in patients with 2A and 2N VWD. This prospective study showed that the rate of biologic response to DDAVP is relatively low not only in type 2 but also in type 1 VWD when uniform and stringent criteria for patient selection and responsiveness are applied. (C) 2004 by The American Society of Hematology. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
103
issue
6
pages
2032 - 2038
publisher
American Society of Hematology
external identifiers
  • pmid:14630825
  • wos:000220123400017
  • scopus:12144289138
ISSN
1528-0020
DOI
10.1182/blood-2003-06-2072
language
English
LU publication?
yes
id
6c0f3e75-448e-4b6b-8c55-73cac54e6c0a (old id 899283)
date added to LUP
2008-01-10 14:25:08
date last changed
2017-10-22 03:44:55
@article{6c0f3e75-448e-4b6b-8c55-73cac54e6c0a,
  abstract     = {This study prospectively evaluated the rate of biologic response to desmopressin (DDAVP) in 66 patients with type I or 2 von Willebrand disease (VWD), each of whom had, on the basis of available records, a clinically significant bleeding history and at least one of the following laboratory abnormalities: bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity (VWF:RCo) less than 10 IU/dL, factor VIII coagulant activity (FVIII:C) less than 20 IU/dL (severe VWD). Before the study, responsive patients were defined as those who, 2 hours after infusion of 0.3 mug/kg DDAVP, had increased baseline values of VWF:RCo and FVIII:C by at least 3-fold and achieved levels of at least 30 IU/dL for both and a BT of 12 minutes or less. The rate of biologic response varied according to VWD types and was higher in type 1 (7 of 26, 27%) than in type 2 (7 of 40,18%) (type 2A [1 of 15, 7%], type 2M [3 of 21, 14%], type 2N [3 of 4,75%]). Mutations in the VWF gene were previously known or newly identified in most patients with types 2A (n = 15 of 15), 2M (n = 15 of 21), and 2N (n = 4 of 4), but in none of those with type 1 VWD. Genotype provided more information than phenotype in predicting individual responses to DDAVP only in patients with 2A and 2N VWD. This prospective study showed that the rate of biologic response to DDAVP is relatively low not only in type 2 but also in type 1 VWD when uniform and stringent criteria for patient selection and responsiveness are applied. (C) 2004 by The American Society of Hematology.},
  author       = {Federici, AB and Mazurier, C and Berntorp, Erik and Lee, CA and Scharrer, I and Goudemand, J and Lethagen, S and Nitu, I and Ludwig, G and Hilbert, L and Mannucci, PM},
  issn         = {1528-0020},
  language     = {eng},
  number       = {6},
  pages        = {2032--2038},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study},
  url          = {http://dx.doi.org/10.1182/blood-2003-06-2072},
  volume       = {103},
  year         = {2004},
}